Attention Investors
Kindly note the Change in PAY IN for BSE A/C No. : 1201250000000691 (CDSL), if you have an NSDL A/C, kindly use INTER DEPOSITORY SLIP. For assistance, please call OR contact: Mr. Dadu, 98339 89807 / 022-6145 1000.    |   Exchanges / Depository: Prevent Unauthorized Transactions in your Trading / Demat account --> Update your Mobile Numbers / email IDs with your Stock Brokers / Depository Participant. Receive alerts on your Registered Mobile / email IDs for trading account transactions and all debit and other important transactions in your demat account directly from Exchange / Depository on the same day ......................Issued in the interest of Investors."     |    KYC : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."     |    ASBA-IPO : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
 ««+1  ««-1
 
Natco Pharma update on legal complaint filed in US     Back
(18 Apr 2024)

NATCO Pharma announced that Fresenius Kabi USA, LLC and Fresenius Kabi Deutschland GmbH (together, “Fresenius”) have filed a complaint against Natco Pharma USA LLC f/k/a Dash Pharmaceuticals LLC in the District Court of Delaware relating to the marketing of Dash Pharmaceuticals Diazepam Injection prefilled syringe in the United States.

Fresenius has not yet effectuated service of the complaint which is required to commence the lawsuit.

Natco Pharma intends to defend the matter accordingly.

Dash Pharmaceuticals LLC had been acquired by Natco Pharma, Inc. and Dash Pharmaceuticals LLC had changed its name to Natco Pharma USA LLC

Top